Merck says 'goodbye, Fosamax,' launches authorized generic

Share this article:
Merck put Fosamax (alendronate sodium) and its $3 billion in total 2007 sales in its rear-view mirror yesterday, following the lapse of patent protection on the osteoporosis drug.

Merck forecast that 2008 sales will decline by at least half that, followed by more attrition later, according to a CNNMoney.com report. Fosamax is part of about $20 billion worth of drugs expected to lose patent protection this year, according to IMS Health stats cited in the report.

This month alone, upcoming patent losses will include GlaxoSmithKline asthma meds Advair ($6 billion in total sales) and Serevent ($500 million in total sales), according to BusinessWeek.

Hoping to stem some of its own losses, Merck quickly launched an authorized generic version of Fosamax (alendronate) through Watson Pharmaceuticals. Under terms of the agreement with Watson, Merck will manufacture and supply the alendronate tablets to Watson, which will market, sell and distribute the pills in the US. Merck will get a cut of US sales. Further details were not disclosed.

Also yesterday, Teva Pharmaceuticals and Barr Labs became the first two generics companies to receive FDA approval to make and sell alendronate.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...